TP53 and endometrial cancer: The 2023 FIGO classification for endometrial cancer (EC) marks a significant advancement in personalized medicine by combining traditional anatomical criteria with critical pathological parameters, such as histological subtype, histopathological grade, the presence of lymphovascular space invasion (LVSI), and molecular alterations, including POLE mutations, p53 status, and MSI-H [3].